|
gptkbp:instanceOf
|
gptkb:Hallucinogen
gptkb:amphetamine
|
|
gptkbp:belongs_to_class
|
gptkb:2C_family
|
|
gptkbp:CASNumber
|
342434-22-2
|
|
gptkbp:chemicalFormula
|
C10H14ClNO2
|
|
gptkbp:discoveredBy
|
gptkb:Alexander_Shulgin
|
|
gptkbp:duration_of_effects
|
4–8 hours
|
|
gptkbp:effect
|
euphoria
hallucinations
altered perception
visual enhancement
|
|
gptkbp:firstSynthesized
|
1983
|
|
gptkbp:hasSMILES
|
COC1=CC(=C(C=C1CCN)OC)Cl
|
|
gptkbp:hasStreet
|
Chlorophen
|
|
gptkbp:IUPACName
|
2-(4-chloro-2,5-dimethoxyphenyl)ethan-1-amine
|
|
gptkbp:legal_status_in_Canada
|
Schedule III controlled substance
|
|
gptkbp:legal_status_in_United_Kingdom
|
Class A drug
|
|
gptkbp:legal_status_in_United_States
|
Schedule I controlled substance
|
|
gptkbp:meltingPoint
|
208–210 °C
|
|
gptkbp:mentions
|
gptkb:PiHKAL
|
|
gptkbp:molecularWeight
|
215.68 g/mol
|
|
gptkbp:PubChem_CID
|
60808
|
|
gptkbp:relatedTo
|
gptkb:2C-B
gptkb:2C-I
|
|
gptkbp:routeOfAdministration
|
oral
insufflation
|
|
gptkbp:bfsParent
|
gptkb:NBOMe_series
gptkb:2C_family
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
2C-C
|